HK Stock Market Move | SUNSHINE PHARMA (06887) rose over 6% in the afternoon, with Class 1 new drug Ologliptin approved for listing. Recently launched an AI intelligent research and development platform.

SUNSHINE PHARMA (06887) rose more than 6% in the afternoon, rising by 6.55% as of the publication, to 46.2 Hong Kong dollars, with a turnover of 30,628.9 million Hong Kong dollars. On the news front, on January 16, the independently developed first-in-class innovative drug Olagliglit Clean Capsule has been approved for marketing by the National Medical Products Administration for improving blood sugar control in adult type 2 diabetes patients as a monotherapy or in combination with metformin. A spokesperson for SUNSHINE PHARMA stated that the approval of Olagliglit Clean is a solid step forward for SUNSHINE PHARMA in the field of chronic disease management. It is worth noting that SUNSHINE PHARMA recently announced that the group continues to deepen its AI strategic layout by launching an AI intelligent R&D platform focused on the PROTAC mechanism, realizing a "dry-wet loop" from the data base. The scale and structure granularity of the data are significantly ahead of existing public databases, providing a comprehensive and systematic data foundation for AI-driven PROTAC rational design, accelerating the rational design and clinical translation of PROTAC lead compounds.